GlassScriptPhysician profile
Heidi R Pusey
NPI 1194012302
$3,833.82
in general payments reported to CMS, 2019-2025
33 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $474 · 2023: $505 · 2024: $2,085 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404 · Travel and Lodging: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.40 |
| Travel and Lodging | $822.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,434.76 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $500.26 | 2022-2025 | Rexulti |
| Abbvie INC. | $335.46 | 2022-2024 | |
| Grifols USA, LLC | $225.50 | 2024-2025 | Prolastin-C Liquid |
| Lundbeck LLC | $166.69 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $134.45 | 2021-2024 | Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $96.48 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.46 | 2021-2023 | |
| Glaxosmithkline, LLC. | $86.25 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $62.25 | 2022-2024 | Evenity, Prolia |
| Medtronic, INC. | $61.62 | 2023 | Guardian Connect |
| Mylan Specialty L.P. | $61.59 | 2024 | Yupelri |
| Lilly USA, LLC | $56.36 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Sunovion Pharmaceuticals INC. | $54.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.85 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Organogenesis INC. | $39.69 | 2024-2025 | Apligraf, Cygnus Dual |
| Smith+Nephew, INC. | $35.34 | 2025 | Pico 7 |
| Surgenex LLC | $26.90 | 2025 | Pellograft, Surmatrix, Surgraft |
| Cashflow Solutions, LLC | $25.52 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Teva Pharmaceuticals USA, INC. | $22.24 | 2024 | Ajovy |
| Viatris Specialty LLC | $22.05 | 2025 | Yupelri |
| Boston Scientific Corporation | $21.64 | 2024 | |
| Reprise Biomedical, INC. | $20.74 | 2025 | Miro3d |
| Abbott Laboratories | $20.12 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $19.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.53 | 2024 | Jardiance |
| Radius Health, INC. | $18.14 | 2024 | Tymlos |
| Integra Lifesciences Corporation | $16.77 | 2025 | Tcc-Ez |
| Aimmune Therapeutics, INC. | $15.62 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $15.48 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.95 | 2022 | |
| Mimedx Group, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Pusey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.